Edgewise Therapeutics (EWTX) Current Assets (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Current Assets data on file, last reported at $509.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 15.03% year-over-year to $509.8 million; the trailing twelve-month figure through Mar 2026 stood at $509.8 million (up 15.03% YoY), and the FY2025 full-year result was $543.4 million, up 14.28% from the prior year.
• Current Assets retreated to $509.8 million in Q1 2026, from $543.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $603.3 million in Q2 2025 to a low of $253.3 million in Q2 2022.
• A 5-year average of $425.5 million and a median of $443.2 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slipped 19.51% in 2023 and jumped 67.64% in 2024, its largest moves.
• Tracing EWTX's Current Assets over 5 years: stood at $357.0 million in 2022, then fell by 8.4% to $327.0 million in 2023, then surged by 45.41% to $475.5 million in 2024, then climbed by 14.28% to $543.4 million in 2025, then retreated by 6.18% to $509.8 million in 2026.
• Business Quant data shows EWTX's Current Assets at $509.8 million in Q1 2026, $543.4 million in Q4 2025, and $573.9 million in Q3 2025.